金河生物(002688) - 2022 Q2 - 季度财报

Financial Performance - The company's operating revenue for the first half of 2022 was CNY 1,125,411,759.81, representing a 17.11% increase compared to CNY 961,006,050.74 in the same period last year[19]. - The net profit attributable to shareholders decreased by 15.27% to CNY 86,691,851.01 from CNY 102,316,936.86 year-on-year[19]. - The net cash flow from operating activities fell by 32.68% to CNY 73,560,711.95, down from CNY 109,272,456.61 in the previous year[19]. - Basic and diluted earnings per share decreased by 31.04% to CNY 0.1111 from CNY 0.1611 in the same period last year[19]. - The net profit after deducting non-recurring gains and losses was CNY 83,731,221.29, down 9.46% from CNY 92,478,789.74 year-on-year[19]. - The company reported a decrease in the weighted average return on net assets to 3.50% from 6.22% in the previous year[19]. - The company reported a total comprehensive income of CNY 132,235,235.30 for the first half of 2022, compared to CNY 116,593,404.52 in the previous year[196]. - The total profit amounted to CNY 44,860,214.58, compared to CNY 43,225,304.65 in the previous year, indicating an increase of about 3.8%[199]. Revenue Breakdown - Revenue from veterinary chemical drugs was 482.95 million yuan, a decrease of 1.58%, accounting for 42.91% of total revenue[37]. - Revenue from veterinary biological products was 143.99 million yuan, down 10.41%, making up 12.80% of total revenue[37]. - Environmental business revenue increased by 70.68% to 58.68 million yuan, representing 5.21% of total revenue[37]. - The agricultural product processing segment saw a revenue increase of 59.23% to 368.81 million yuan, accounting for 32.77% of total revenue[37]. - The company's revenue from the animal health segment decreased by CNY 29.0013 million, a decline of 4.37% compared to the same period last year[39]. Cost and Expenses - Operating costs rose to CNY 803.30 million, reflecting a 28.41% increase year-on-year, with significant contributions from the animal health and agricultural processing sectors[59]. - The average gross margin for biological products is reported at 58.72% due to favorable market demand and tax incentives[36]. - The average procurement price of corn starch decreased by approximately 7.40% compared to the same period last year, while coal prices increased by over 59%[40]. - The financial expenses decreased significantly by 87.48% to CNY 4.28 million, due to lower borrowing costs and favorable exchange rate impacts[59]. Investment and R&D - The company reported a 20.93% increase in R&D investment, totaling CNY 46.08 million, aimed at enhancing product development and market competitiveness[59]. - The company continues to invest in vaccine product R&D, collaborating with strong research institutions to reduce associated risks[105]. Market and Operational Strategy - The company is focusing on new product development in veterinary drugs, including new vaccines and pet medications[27]. - The company anticipates a favorable market for veterinary chemical drugs and vaccines due to the recovery in pig farming profitability in 2022[36]. - The company is positioned to strengthen its leading role in the veterinary drug industry as market concentration increases following the implementation of new GMP standards[34]. - The company is expanding its market presence internationally, with significant sales in the U.S., Canada, and several Latin American countries[28]. Environmental Compliance - The company reported a total emission of 52.27 tons of particulate matter, with a concentration of 12.23 mg/m³, complying with the emission standard[114]. - Sulfur dioxide (SO2) emissions were recorded at 68.626 tons, with a concentration of 123.01 mg/m³, below the standard limit of 200 mg/m³[114]. - Nitrogen oxides (NOX) emissions totaled 105.302 tons, with a concentration of 186.505 mg/m³, adhering to the emission standard[114]. - The company has implemented real-time monitoring systems for emissions, ensuring compliance with environmental regulations[116]. - The company has established a comprehensive pollution prevention and control system, ensuring the effective treatment of emissions and wastewater[117]. Fundraising and Financial Management - The total amount of funds raised by the company through a non-public offering was approximately RMB 820 million, with a net amount of RMB 802 million after deducting issuance costs[78]. - The company has established a fundraising management system to ensure compliance with relevant laws and regulations, and the funds are stored in a dedicated account[81]. - The company has not engaged in any securities or derivative investments during the reporting period[75][76]. - The company plans to continue investing the raised funds into its projects as per the approved budget[81]. Shareholder Information - The company plans to repurchase shares with a total fund of no less than RMB 120 million and no more than RMB 200 million, having repurchased 10,010,010 shares, accounting for 1.28% of the total share capital, with a total transaction amount of RMB 45,982,364[156]. - The largest shareholder, Inner Mongolia Jinhe Holdings Co., Ltd., holds 241,758,670 shares, representing 30.98% of total shares[172]. - The company’s stock structure includes 620,866,224 unrestricted shares, which represent 79.56% of the total shares[168]. - The company’s total share capital remains unchanged at 780,422,398 shares, indicating stability in its equity structure[169].